Expert Interview
Discussing Celldex Therapeutics' Barzolvolimab (CDX-0159) for Chronic Inducible Urticarias
Ticker(s): CLDXInstitution: Trinity Health Michigan and Allergy & Immunology Associates of Ann Arbor
- Board-certified Allergist & Immunologist and Pediatrician
- Treats thousands of patients with chronic inducible urticarias annually
- Specializes in allergic and immunologic diseases including food allergy, environmental allergies, asthma, and anaphylaxis; involved in clinical research and education related to allergic diseases and community allergy management, and serves as a clinical investigator participating in trials including studies of emerging biologic therapies such as those being developed by Celldex.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
